{
    "clinical_study": {
        "@rank": "84007", 
        "acronym": "BIOFLOW-IV", 
        "arm_group": [
            {
                "arm_group_label": "Abbott Laboratories Xience", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects assigned to Abbott Laboratories Xience can be treated with either the Xience Prime or Xience Xpedition drug eluting stent (DES)."
            }, 
            {
                "arm_group_label": "Biotronik Orsiro", 
                "arm_group_type": "Experimental", 
                "description": "Subjects assigned to Biotronik Orsiro will be treated with Biotronik Orsiro"
            }
        ], 
        "brief_summary": {
            "textblock": "BIOFLOW-IV is a prospective, international, multicenter, randomised controlled trial. The\n      purpose of this trial is to compare the Biotronik Orsiro drug eluting stent system with the\n      Xience Prime / Xience Xpedition (Xience)drug eluting stent system in de novo coronary\n      lesions. The study is powered for non-inferiority with respect to Target Vessel\n      Failure(TVF)at 12 months."
        }, 
        "brief_title": "Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus-eluting Stent", 
        "completion_date": {
            "#text": "October 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  Subject must provide written informed consent\n\n          -  The target reference vessel diameter (RVD) is \u2265 2.50 mm and \u2264 3.75 mm assessed either\n             visually or by online QCA.\n\n          -  Target lesion length is \u2264 26 mm (assessed either visual estimate or by online QCA)\n             and can be covered by one study stent\n\n          -  Single de novo lesion with \u2265 50% and < 100% stenosis in up to 2 coronary arteries\n\n        Main Exclusion Criteria:\n\n          -  Subject has evidence of myocardial infarction within 72 hours prior to the index\n             procedure\n\n          -  Planned intervention of non-target vessel(s) within 30 days after the index procedure\n\n          -  Planned intervention of target vessel(s) after the index procedure\n\n          -  Target lesion is located in the left main\n\n          -  Target lesion is located in or supplied by an arterial or venous bypass graft\n\n          -  Target lesion involves a side branch > 2.0 mm in diameter by visual estimate or by\n             online QCA\n\n          -  Proximal or distal to the target lesion located stenosis that might require future\n             revascularization or impede run off"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "585", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939249", 
            "org_study_id": "C1204"
        }, 
        "intervention": [
            {
                "arm_group_label": "Abbott Laboratories Xience", 
                "intervention_name": "Abbott Laboratories Xience", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Biotronik Orsiro", 
                "intervention_name": "Biotronik Orsiro", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sirolimus"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "contact": {
                "email": "ralph.toelg@segebergerkliniken.de", 
                "last_name": "Ralph T\u00f6lg, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Bad Segeberg", 
                    "country": "Germany", 
                    "zip": "23795"
                }, 
                "name": "Segeberger Kliniken GmbH"
            }, 
            "investigator": {
                "last_name": "Ralph T\u00f6lg, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "BIOTRONIK-A Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects With up to Two de Novo Coronary Artery Lesions - IV", 
        "overall_contact": {
            "email": "lennart.ivarsson@biotronik.com", 
            "last_name": "Lennart Ivarsson, PhD", 
            "phone": "+41 44 864", 
            "phone_ext": "5518"
        }, 
        "overall_contact_backup": {
            "email": "yuki.mizukami@biotronik.co.jp", 
            "last_name": "Yuki Mizukami", 
            "phone": "+81 3 3473", 
            "phone_ext": "7483"
        }, 
        "overall_official": [
            {
                "affiliation": "Okinawa Tokushukai Shonan Kamakura General Hospital", 
                "last_name": "Shigeru Saito, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Onze Lieve Vrouwe Gasthuis", 
                "last_name": "Ton Slagboom, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Target Vessel Failure", 
            "safety_issue": "Yes", 
            "time_frame": "12 months post index procedure"
        }, 
        "removed_countries": {
            "country": "Japan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939249"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of clinically-driven target lesion revascularization (TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "1-month, 6-month, 12-month, 2-year, 3-year, 4-year and 5-year"
            }, 
            {
                "measure": "Rate of clinically-driven target vessel revascularization (TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "1-month, 6-month, 12-month, 2-year, 3-year, 4-year and 5-year"
            }, 
            {
                "measure": "Rate of target lesion failure (TLF), defined as composite of cardiac death, target vessel Q-wave or non-Q wave myocardial infarction (MI), emergent coronary artery bypass graft (CABG), any clinically-driven TLR", 
                "safety_issue": "Yes", 
                "time_frame": "1-month, 6-month, 12-month, 2-year, 3-year, 4-year and 5-year"
            }
        ], 
        "source": "Biotronik AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biotronik AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}